Innovent Announces 2026 Interim Results and Business Updates
Transforming from Regional Leader to Global Premier: A Clear Strategic Path for Growth and Globalization SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class...
Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab New anatomic data demonstrates OLN324...